News

Back

Exothera completes its range of state-of-the-art technologies by acquiring the new generation of the NevoLine™ Upstream platform for its new site in Belgium

January 28th 2021

BioPark

Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO) delivering customized process development and GMP (Good Manufacturing Practices) manufacturing services for gene therapy and viral vector-based vaccines, announces today that it has acquired the NevoLine™ Upstream manufacturing platform, the latest equipment of Univercells Technologies.
Based on principles of intensification and chaining, this high-performance, low-footprint upstream manufacturing platform is an integrated and automated solution for the cost-effective production of viral vaccines, viral vectors and oncolytic viruses. Please discover the press release here.